Abstract:Abstract We have developed an algorithm and implemented it in a software platform for the purpose of developing new anti-tumor drugs in the form of small molecules. In this study, we focused on generating molecules specifically for the treatment of lung cancer patients. To begin with, we employed deep learning (DL) techniques to evaluate the genes associated with poor clinical outcomes in lung cancer patients. By utilizing generative adversarial neural networks (GAN), we acquired additional patient data. The results of each experiment were presented as a list of genes ordered by their impact on the desired effect. We then intersected the lists of genes obtained from experiments with overall survival (OS) and progression-free interval (PFI) data. This allowed us to identify a set of genes whose expression was correlated with poor prognosis. In order to enhance the precision, we trained another DL model to distinguish between normal and tumor tissue based on gene expression. By doing so, we were able to identify the smaller set of genes that could be targeted. Subsequently, we developed a module that predicts the interactions between inhibitors and proteins. This involved representing protein amino acid sequences and chemical compound formulas in vector form, and a virtual screening of the Pubchem database. The implementation of the Drug-protein interactions module resulted in a dataset of 118,379 pairs, including 19,250 pairs describing compounds bound to proteins, and 99,129 precedents describing non-bound ones. DLwas applied, yielding a ROC-AUC of 0.86. Following the search for candidate molecules, we obtained 160,000 pairs with a predicted interaction probability above 0.99, as well as 2,921 pairs with probability of 1.0. Additionally, we created a DL-based module to predict the IC50 values in cell line experiments. Virtual pre-clinical trials were conducted using the selected inhibitors to identify relevant cell lines for subsequent laboratory experiments. Through this process, we obtained formulas for several molecules that demonstrated predicted binding to specific proteins. During the cell experiment emulation, our feature importance algorithm selected 129 genes. For the cell experiment emulation stage, we specifically chose interactions with a probability of at least 0.9. We prioritized molecules that acted on the minimum number of cell lines with a higher probability, thus ensuring higher specificity. Ultimately, we selected 5 small molecules as potential candidates, as well as certain cell lines for their validation. The NLP technologies utilized in this study demonstrated their effectiveness in processing tens of thousands of articles. The pipeline of methods presented in this paper lays the groundwork for automated AI-driven drug discovery. We have showcased the application of modern machine learning methods, particularly DL, as well as the methods used to prepare the initial data for the learning algorithms. The performance of these methods has been validated through cross-validation using data from publicly available sources. Citation Format: Dmitrii K Chebanov, Vsevolod A Misyurin, Nadezhda S Tatevosova. Deep learning-driven drug discovery: A breakthrough algorithm and its implication in lung cancer therapy development [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A014.

Abstract PR001: Learning to adapt: Rational personalization of adaptive therapy using deep reinforcement learning

Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer

Abstract PR003: Multi-drug adaptive therapy protocol in vitro: An exercise in optimization for neuroblastoma

Deep reinforcement learning for personalized treatment recommendation

Abstract A017: Computational and mouse models of adaptive therapy with multiple drugs in breast cancer

Reinforcement Learning in Clinical Medicine: a Method to Optimize Dynamic Treatment Regime over Time.

Deep Reinforcement Learning for Fractionated Radiotherapy in Non-Small Cell Lung Carcinoma

Abstract 1174: Enhancing the utilization of deep learning to predict patient response in small immunotherapy cohorts using real-world data

Abstract 907: ScreenDL: A transfer learning framework integrating tumor omics and functional drug screening for personalized clinical drug response prediction

Reinforcement Learning and PK‐PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma

Abstract A025: Adaptive therapy: Leveraging evolutionary dynamics for colorectal cancer management in vivo

Abstract 7286: Optimizing prediction of metastatic castration-resistant prostate cancer: Multimodal fusion of clinicopathological and genomic features with machine learning

A clinical decision support system for AI-assisted decision-making in response-adaptive radiotherapy (ARCliDS)

Abstract 3537: Assessing machine learning models of drug response predictions using orthotopic patient-derived xenograft

Single patient learning for adaptive radiotherapy dose prediction

Deep Reinforcement Learning for Dynamic Treatment Regimes on Medical Registry Data

Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach

Abstract A014: Deep learning-driven drug discovery: A breakthrough algorithm and its implication in lung cancer therapy development

DTR-Bench: An in silico Environment and Benchmark Platform for Reinforcement Learning Based Dynamic Treatment Regime

Abstract 6446: ResponderIDTM KRAS: Biology-driven machine learning to personalize KRAS inhibitor therapeutics

Abstract IA007: Improving cancer treatment through data-driven game theory